UK Clinical Trial Recruitment Drops 25% Despite Government Reform Efforts
核心洞察
Patient recruitment into commercial clinical trials in the UK fell 25% in 2024/25 to just over 19,000 participants, reaching the lowest level since 2017/18.
Only 3.4% of clinical trial participants in England were recruited into industry trials in 2024, despite an overall increase in clinical research participation since the pandemic.
While the number of new industry trials initiated increased by 36% to 578, slow site setup times and missed recruitment targets continue to hamper the UK's competitiveness.
Patient recruitment into commercial clinical trials in the UK has fallen dramatically by 25% in 2024/25 to just over 19,000 participants, marking the lowest level since 2017/18, according to the latest annual report from the Association of the British Pharmaceutical Industry (搜索) (ABPI (搜索)). This decline comes despite government efforts to reform the clinical trials environment and threatens the ambitious target of quadrupling trial participants by 2027.
The disappointing recruitment figures emerge more than two years after Lord O'Shaughnessy's report identified the UK's declining position as a clinical research hub and recommended sweeping changes to reverse the trend. The government had committed to reducing clinical trial set-up times from around 250 to 150 days through a series of targets: delivering regulatory decisions within 60 days, opening sites to recruitment within 60 days of approval, and recruiting first patients within 30 days of trial opening.
Implementation Challenges Persist
While regulatory decision targets are being met, significant bottlenecks remain in trial execution. According to the ABPI (搜索) report, only 27% of sites opened for recruitment on time, and just 41% recruited their first patients within the 30-day allocation. These delays are contributing to what pharmaceutical companies describe as slow set-up times and significantly lower recruitment targets for UK sites compared to other European countries.
The recruitment crisis is particularly concerning given that only 3.4% of participants in clinical trials in England during 2024 were recruited into industry trials within the NHS, despite overall participation in clinical research increasing since the pandemic.
Mixed Progress Indicators
The clinical trials landscape presents a complex picture of both progress and setbacks. On the positive side, the UK saw a 36% increase in the number of new industry trials initiated to 578, and climbed from eighth place to sixth place globally for phase 3 trial starts. However, these gains are being undermined by the fundamental challenge of patient recruitment.
Competition with other countries remains intense, with Spain now topping the list for European locations while China continues to expand its global dominance in clinical trials, according to the ABPI (搜索) assessment.
Economic and Patient Access Implications
Dr Janet Valentine, the ABPI (搜索)'s head of research and innovation policy, emphasized the broader implications of the recruitment decline. "Industry clinical trials bring widespread benefits for patients, the NHS, and the economy," she stated. "While the increase in the number of industry trials initiated in the UK is positive, the low number of patients taking part is selling UK patients short of the opportunity to participate in studies of the latest therapeutic innovations."
The ABPI (搜索) argues that this decline reduces opportunities for patients to access new medicines, particularly in cases where few other treatment options exist. The organization warns that fewer participants could discourage global pharmaceutical companies from choosing the UK for their studies, potentially impacting the billions that commercial research brings to the wider economy and the direct financial benefits delivered to the NHS.
Strategic Recommendations
To address these challenges, the ABPI (搜索) report makes several key recommendations, led by a call for investigative sites to "set and meet higher recruitment targets." The organization also advocates for executive-level accountability for clinical trials across the NHS and emphasizes the need to maximize the impact of the £300 million VPAG Clinical Trials Investment Programme, a public-private partnership announced to improve UK commercial trials delivery.
Dr Valentine noted that while "the government and system partners are working hard to improve the environment for delivering industry trials in the UK," the report highlights where these efforts could have the greatest impact, particularly through fully exploiting the industry-funded investment programme designed to enhance the country's commercial trials performance.